Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
Advertisement
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road?

  1. Ezio Bonifacio⇓
  1. Center for Regenerative Therapies, Dresden University of Technology Dresden, Dresden, Germany
  1. Corresponding author: Ezio Bonifacio, ezio.bonifacio{at}crt-dresden.de.
Diabetes 2012 Sep; 61(9): 2214-2215. https://doi.org/10.2337/db12-0648
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

We strive but struggle to translate immune therapies that have been shown to be effective in preclinical models of autoimmune diabetes into use with patients. Only a small proportion of these therapies are actually tested in humans, and of these, efficacy (even short-term) has been achieved in less than a handful (1). A striking example of this struggle is provided by a clinical trial reported in the current issue of Diabetes (2). After setting everything up correctly with convincing data in preclinical models (3,4), an attractive hypothesis (5), and safety studies in animals, the Immune Tolerance Network (ITN) conducted a single-arm trial of combination therapy with interleukin (IL)-2 (4 weeks) together with rapamycin (12 weeks) in patients who had recently developed type 1 diabetes. Treatment successfully led to a respectful increase in circulating regulatory T cell (Treg) numbers. However, the therapy failed to halt β-cell loss and even transiently exacerbated loss of β-cell function. Interestingly, IL-2 seems to have been responsible for both the increased Treg numbers and the loss of β-cell function. It also seems that IL-2 acted on effector arms of innate immunity and that this may have led to the negative effects on the β-cell.

The rationale for IL-2 therapy in type 1 diabetes is relatively strong (Fig. 1), with reproducible genetic associations with genes of the IL-2 pathway (6) and functional defects in IL-2 signaling (7–9), plus successful use of IL-2 in preclinical models of autoimmune diabetes (3,4) and therapeutic benefit in patients with immune-mediated disorders (10,11). One can always find ways to be …

View Full Text
PreviousNext
Back to top
Advertisement
Diabetes: 61 (9)

In this Issue

September 2012, 61(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road?
Ezio Bonifacio
Diabetes Sep 2012, 61 (9) 2214-2215; DOI: 10.2337/db12-0648

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road?
Ezio Bonifacio
Diabetes Sep 2012, 61 (9) 2214-2215; DOI: 10.2337/db12-0648
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
  • Fatty Acids and Insulin Secretion: From FFAR and Near?
  • Strong Heart, Low Ceramides
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org
Advertisement

© 2019 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.